Dr. med. Lukas Wildi

Originalarbeiten

1. Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort.
   Hebeisen M, Neuenschwander R, Scherer A, Exer P, Weber U, Tamborrini G, Micheroli R, Wildi LM, Zufferey P, Nissen MJ, Villiger PM, Bernhard J, Finckh A, van der Horst-Bruinsma IE, Sieper J, Landewé R, van der Heijde D, Ciurea A; rheumatologists of the Swiss Clinical Quality Management Program.
   J Rheumatol. 2018 Apr;45(4):506-512. doi: 10.3899/jrheum.170166.
2. Nodular Regenerative Hyperplasia of the Liver: A Rare Vascular Complication in Systemic Sclerosis.
   Graf L, Dobrota R, Jordan S, Wildi LM, Distler O, Maurer B.
   J Rheumatol. 2018 Jan;45(1):103-106. doi: 10.3899/jrheum.170292.
3. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort.
   Molnar C, Scherer A, Baraliakos X, de Hooge M, Micheroli R, Exer P, Kissling RO, Tamborrini G, Wildi LM, Nissen MJ, Zufferey P, Bernhard J, Weber U, Landewé RBM, van der Heijde D, Ciurea A; Rheumatologists of the Swiss Clinical Quality Management Program.
   Ann Rheum Dis. 2017 Sep 22. pii: annrheumdis-2017-211544. doi: 10.1136/annrheumdis-2017-211544.
   PMID: 28939631
4. Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis.
   Micheroli R, Hebeisen M, Wildi LM, Exer P, Tamborrini G, Bernhard J, Möller B, Zufferey P, Nissen MJ, Scherer A, Ciurea A; Rheumatologists of the Swiss Clinical Quality Management Program.
   Arthritis Res Ther. 2017 Jul 19;19(1):164. doi: 10.1186/s13075-017-1372-3.
   PMID: 28724442
5. MRI findings in the knee before and after running, with the focus on long distance running: Documentation of irreversible structural damage? A systematic review.
   Hoessly LM, Wildi LM. Am J Sports Med. 2017 Apr;45(5):1206-1217.
6. Computer-based diagnostic expert systems in rheumatology: where do we stand in 2014?
   Alder H, Michel BA, Marx C, Tamborrini G, Langenegger T, Bruehlmann P, Steurer J, Wildi LM.
   Int J Rheumatol. 2014;2014:672714
7. Relevant baseline characteristics for describing patients with knee osteoarthritis: results from a Delphi survey.
   Wildi LM, Hensel A, Wertli M, Michel BA, Steurer J.
   BMC Musculoskelet Disord. 2013 Dec 30;14:369
8. Assessment of cartilage changes over time in knee osteoarthritis disease-modifying osteoarthritis drug trials using semiquantitative and quantitative methods: pros and cons.
   Wildi LM, Martel-Pelletier J, Abram F, Moser T, Raynauld JP, Pelletier JP.
   Arthritis Care Res (Hoboken). 2013 May;65(5):686-94
9. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI.
   Wildi LM, Raynauld JP, Martel-Pelletier J, Beaulieu A, Bessette L, Morin F, Abram F, Dorais M, Pelletier JP.
   Ann Rheum Dis. 2011 Jun;70(6):982-9
10. Relationship between bone marrow lesions, cartilage loss and pain in knee osteoarthritis: results from a randomised controlled clinical trial using MRI.
    Wildi LM, Raynauld JP, Martel-Pelletier J, Abram F, Dorais M, Pelletier JP.
    Ann Rheum Dis. 2010 Dec;69(12):2118-24
11. Pseudocystic degeneration of the lumbar ligamentum flavum: a little known entity.
    Wildi LM, Kurrer MO, Benini A, Weishaupt D, Michel BA, Brühlmann P..
    J Spinal Disord Tech. 2004 Oct;17(5):395-400
12. Cross-cultural adaptation of the German version of the spinal stenosis measure.
    Wertli MM, Steurer J, Wildi LM, Held U.
    Eur Spine J. 2014 Jun;23(6):1309-19
13. Reliability and sensitivity to change of IW-TSE versus DESS magnetic resonance imaging sequences in the assessment of bone marrow lesions in knee osteoarthritis patients: Longitudinal data from the Osteoarthritis Initiative (OAI) cohort.
    Raynauld JP, Wildi LM, Abram F, Moser T, Pelletier JP, Martel-Pelletier J. J. Biomedical Science and Engineering, 2013. 6: p. 337-45
14. Total Knee Replacement as a Knee Osteoarthritis Outcome: Predictors Derived from a 4-Year Long-Term Observation following a Randomized Clinical Trial Using Chondroitin Sulfate.
    Raynauld JP, Martel-Pelletier J, Dorais M, Haraoui B, Choquette D, Abram F, Beaulieu A, Bessette L, Morin F, Wildi LM, Pelletier JP.
    Cartilage. 2013 Jul;4(3):219-26
15. Risk factors predictive of joint replacement in a 2-year multicentre clinical trial in knee osteoarthritis using MRI: results from over 6 years of observation.
    Raynauld JP, Martel-Pelletier J, Haraoui B, Choquette D, Dorais M, Wildi LM, Abram F, Pelletier JP.
    Ann Rheum Dis. 2011 Aug;70(8):1382-8

Narrative Reviews

1. Osteoarthritis : What internists should know.
   Wildi L
   Internist (Berl). 2015 May;56(5):527-43
2. Pharmacological therapy of arthrosis.
   Wildi LM
   Z Rheumatol. 2013 Nov;72(9):885-94
3. Future therapeutics for osteoarthritis.
   Martel-Pelletier J, Wildi LM, Pelletier JP.
   Bone. 2012 Aug;51(2):297-311

Case Reports

1. Reversible male infertility under treatment with an anti-TNFα agent: a case report.
   Wildi LM, Haraoui B.
   Ann Rheum Dis. 2012 Mar;71(3):473-4

Buchkapitel

1. “Biomarkers in Osteoarthritis” in “Understanding Osteoarthritis from Bench to Bedside”
   Wildi LM, Tamborrini G
   Editors Martel-Pelletier J. and Pelletier J.P. Research Signpost, Kerala, India